Movement Alert｜INSILICO Rises 9.6% in Regular Trading, NLRP3 Inhibitor Receives Clinical Approval Plus JPMorgan Initiates Coverage

Market Focus08-10

On August 10, INSILICO rose 9.6% in regular trading, trading at 50.9 HKD/share, with turnover of 92.32 million HKD. The rally was driven by dual catalysts: the NMPA clinical trial approval of its blood-brain barrier penetrating NLRP3 inhibitor and JPMorgan's initiation of coverage.

Specifically, INSILICO and Hengtai Bio's co-developed oral NLRP3 inhibitor ISM8969/HT-001 received NMPA approval for clinical trials targeting Parkinson's disease. Unlike other peripherally-restricted NLRP3 inhibitors in clinical development, ISM8969/HT-001 can penetrate the blood-brain barrier and enter the central nervous system, offering therapeutic potential for neuroinflammation-related diseases. The clinical trial will evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy in Parkinson's patients.

Additionally, JPMorgan initiated coverage on INSILICO with an \"Overweight\" rating and a target price of 71 HKD, implying approximately 39% upside from the current level. This follows the company's H1 profit alert projecting revenue of USD 103-107 million (up ~275% YoY) and net profit of USD 33.5-39.5 million, marking a turnaround from a loss of USD 19.2 million in the prior year period.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment